Onset time and durability of huntingtin suppression in rhesus putamen after direct infusion of antihuntingtin siRNA

Richard Grondin, Pei Ge, Qingmin Chen, Jessica E. Sutherland, Zhiming Zhang, Don M. Gash, David K. Stiles, Gregory R. Stewart, Dinah W.Y. Sah, William F. Kaemmerer

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


One possible treatment for Huntington's disease involves direct infusion of a small, interfering RNA (siRNA) designed to reduce huntingtin expression into brain tissue from a chronically implanted programmable pump. Here, we studied the suppression of huntingtin mRNA achievable with short infusion times, and investigated how long suppression may persist after infusion ceases. Rhesus monkeys received 3 days of infusion of Magnevist into the putamen to confirm catheter patency and fluid distribution. After a 1-week washout period, monkeys received radiolabeled siRNA targeting huntingtin. After 1 or 3 days of siRNA delivery, monkeys were either terminated, or their pumps were shut off and they were terminated 10 or 24 days later. Results indicate that the onset of huntingtin mRNA suppression in the rhesus putamen occurs rapidly, achieving a plateau throughout the putamen within 4 days. Conversely, loss of huntingtin suppression progresses slowly, persisting an estimated 27-39 days in the putamen and surrounding white matter. These findings indicate the rapid onset and durability of siRNA-mediated target gene suppression observed in other organs also occurs in the brain, and support the use of episodic delivery of siRNA into the brain for treatment of Huntington's disease and possibly other neurodegenerative diseases.

Original languageEnglish
Article numbere245
Pages (from-to)e245
JournalMolecular Therapy - Nucleic Acids
Issue number6
StatePublished - Jun 2015

Bibliographical note

Funding Information:
CHDI Foundation, Inc., a privately-funded not-for-profit biomedical research organization exclusively dedicated to developing therapies that slow the progression of Huntington disease, provided financial support for this study under a research agreement between CHDI Foundation, Medtronic, and Alnylam Pharmaceuticals. At the time this study was conducted, Pei Ge, Qingmin Chen, Jessica Sutherland, and Dinah Sah were salaried employees of Alnylam Pharmaceuticals, and David Stiles, Gregory Stewart and William Kaemmerer were salaried employees of Medtronic, Inc.

Publisher Copyright:
© 2015 The American Society of Gene & Cell Therapy All rights reserved.


  • Convection enhanced delivery
  • Huntington's disease
  • Putamen
  • Rhesus
  • SiRNA

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Onset time and durability of huntingtin suppression in rhesus putamen after direct infusion of antihuntingtin siRNA'. Together they form a unique fingerprint.

Cite this